medigraphic.com
Colegio de Medicos y Cirujanos República de Costa Rica

2014, Number 611

<< Back Next >>

Rev Med Cos Cen 2014; 71 (611)

Vacunación contra el VPH

Ramírez SKT

Language: Spanish
References: 14
Page: 529-532
PDF size: 205.09 Kb.


ABSTRACT

The human papillomavirus (HPV) is highly prevalent in the world population, and is the cause of high morbidity and mortality. HPV vaccines are available to prevent HPV associated diseases including cervical cancer and genital warts.


REFERENCES

  1. Agorastos, T., Chatzigeorgiou, K., Brotherton, J., et al. Safety of human papillomavirus vaccines: A review of the international experience so far. Vaccine27 (2009) 7270–7281

  2. Arguedas O. Vacunación contra el virus del papiloma humano en circunstancias especiales. Actualización médica periódica (2010), 1-11

  3. Díaz, M. Counseling the patient with HPV disease. Obstet Gynecol Clin N Am 40 (2013) 391–402

  4. Fundación INCIENSA. Estudio de la vacuna contra el virus del papiloma humano en Guanacaste. Addendum al Formulario de Consentimiento Informado Escrito. Institutos de Salud de los Estados Unidos, Bethesda, Maryland, Estados Unidos de América. 2009.

  5. Gattoc, L; Nair, N & Ault, K. Human Papillomavirus Vaccination. Obstet Gynecol Clin N Am 40, (2013), 177–197.

  6. Hariri, S., Markowitz, L., Dunne, E. & et al. Population Impact of HPV Vaccines: Summary of Early Evidence. Journal of Adolescent Health 53, (2013), 679-682.

  7. Kohli, M., Lawrence, D. & et al. Modeling the impact of the difference in cross-protection data between a human papillomavirus (HPV)- 16/18 ASO4-adjuvanted vaccine and a human papillomavirus (HPV)- 6/11/16/18 vaccine in Canada. MC Public Health (2012),12:872

  8. Ma, B. & Roden, R. Current Status of Human Papillomavirus Vaccines. Journal of the Formosan Medical Association (2010), 109 (7), 481- 483.

  9. Malagón T, Drolet M, Boily MC, et al. Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis. Lancet Infect Dis 2012;12(10):781–9.

  10. Paul, P. & Fabio, A. Literature review of HPV vaccine delivery strategies: Considerations for school- and non-school based immunization program. Vaccine 32 (2014) 320– 326

  11. Saslow D., Castle, P., Cox, T. & et al. American Cancer Society Guideline for Human Papillomavirus (HPV) Vaccine Use to Prevent Cervical Cancer and Its Precursors. A Cancer Journal for clinicians (2007), 7-28.

  12. U.S. Department Health and Human Services. FDA Licensure of Bivalent Human Papillomavirus Vaccine (HPV2, Cervarix) for Use in Females and Updated HPV Vaccination Recommendations from the Advisory Committee on Immunization Practices (ACIP). Centers for Disease Control and Prevention Morbidity and Mortality Weekly Report, (2010) 59 (20), 626- 629

  13. van der Burg S. & Palefsky, J. Human immunodeficiency virus and human papilloma virus - why HPV-induced lesions do not spontaneously resolve and why therapeutic vaccination can be successful. Journal of Translational Medicine (2009), 7: 108-113.

  14. Weinstein L., B. E. (2009). Screening and Prevention: Cervical Cancer. Primary Care: Clinics in Office Practice, 36, 559–574




2020     |     www.medigraphic.com